What is Stuart Therapeutics?
Established in 2017 and headquartered in Stuart, Florida, Stuart Therapeutics is dedicated to the development of novel therapeutics. Its core focus lies in PolyCol, a proprietary collagen mimetic peptide platform designed to address unmet medical needs. The company's pre-clinical stage signifies its ongoing efforts in research and development, aiming to translate scientific discoveries into viable treatment options.
How much funding has Stuart Therapeutics raised?
Stuart Therapeutics has raised a total of $11M across 1 funding round:
Series A
$11M
Series A (2021): $11M with participation from Wisconsin Alumni Research Foundation, BioBrit , LLC, MiMo Capital LLC, and InFocus Capital Partners LLC
Key Investors in Stuart Therapeutics
Wisconsin Alumni Research Foundation
The Wisconsin Alumni Research Foundation (WARF) is a nonprofit foundation managing intellectual property from the University of Wisconsin Madison, focusing on patenting, licensing, and investment to support scientific innovation.
BioBrit , LLC
Undisclosed investor participating in the funding round.
MiMo Capital LLC
Undisclosed investor participating in the funding round.
What's next for Stuart Therapeutics?
The recent major strategic investment indicates a strong vote of confidence in Stuart Therapeutics' technology and future prospects. This capital infusion is expected to accelerate the company's pre-clinical development pipeline, potentially enabling further research, IND-enabling studies, and the progression towards clinical trials. The strategic nature of the funding suggests potential collaborations or partnerships that could enhance market access and development timelines.
See full Stuart Therapeutics company page
